Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Blood Therapeutics Inc.

www.gbt.com

Latest From Global Blood Therapeutics Inc.

Keeping Track Of Thanksgiving Leftovers: Risdiplam, Artesunate Highlight Glut Of Submissions/Filings

Yes, we know they should be out of the fridge by now, but here are the highlights of submissions and filings during the Thanksgiving week.

US FDA Performance Tracker Drug Review

Keeping Track: Oxbryta Approval Headlines Pre-Thanksgiving Week Of News

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Global Blood Therapeutics' Oxbryta Approved Broadly For Sickle Cell Disease

Oxbryta is the second new drug for sickle cell disease approved in just over one week, but it was approved with a broad label for sickle cell disease while Novartis' Adakveo was approved for pain crises.

Approvals Launches

Keeping Track Of User Fee Decisions And Filings: Adakveo, Brukinsa And Fetroja Mark Massive Week Of Novel Approvals

The latest news on US FDA user fee decisions and submissions to the agency.

US FDA Performance Tracker Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Global Blood Therapeutics Inc.
  • Senior Management
  • Ted W Love, MD, Pres. & CEO
    Jeffrey Farrow, CFO
    Jung E Choi, Chief Bus. & Strategy Officer
    David L Johnson, Chief Commercial Officer
    Brian Cathers, PhD, CSO
  • Contact Info
  • Global Blood Therapeutics Inc.
    Phone: (650) 741-7700
    171 Oyster Point Blvd.
    Ste. 300
    South San Francisco, CA 94080
    USA
UsernamePublicRestriction

Register